Cybin Inc. has been granted approval to start the EMBRACE Phase 3 study of CYB003 in Australia, marking a significant milestone in their development of new treatment options for mental health conditions. This study is part of Cybin's Phase 3 multinational program, PARADIGM, and focuses on major depressive disorder.

NRx Pharmaceuticals, listed on NASDAQ as NRXP, has filed a Citizen Petition asking the FDA to prohibit the use of benzethonium chloride in ketamine products due to its toxic nature. The company has presented evidence supporting the safety and stability of their preservative-free ketamine, 'NRX-100', and is also seeking FDA approval for their oral NMDA-targeting drug, 'NRX-101'. Learn more about NRx Pharmaceuticals and stay updated on industry news at PsychedelicNewsWire.com.

Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. highlights the positive Phase 2 study results of their IHL-42X asset, showing significant reduction in Apnoea-Hypopnoea Index. Patient-reported outcomes were also impressive, boosting IXHL's prospects for bringing IHL-42X to market. The company's financial position has improved through strategic financing, and other projects like PSX-001 and IHL-675A are progressing well. Stonegate's valuation model suggests a range of $1.05 to $2.86 for IXHL, with potential for re-ratings based on new information.

Cybin Inc., a neuropsychiatry company, discussed developments in innovative mental health treatments at their recent shareholder meeting, with a focus on promising data for CYB003 and CYB004. Shareholders representing nearly half of the company's common shares were present. Visit Cybin's newsroom for further details.

Cybin Inc., a clinical-stage neuropsychiatry company, shared its Q1 2025 results and updates on its Phase 3 Depression Program and Phase 2 Anxiety Study. The company has expanded its Phase 3 program for major depressive disorder and is close to completing enrollment for its anxiety study. With adequate funding, Cybin is poised to address the pressing need for improved mental health treatments.

NRx Pharmaceuticals' subsidiary HOPE Therapeutics(TM) has received regulatory clearance in Florida to acquire Dura Medical LLC, a clinic specializing in mental health and chronic pain treatment. This acquisition will enhance HOPE's presence in Florida and strengthen their capabilities in utilizing psychedelic medications and neuroplastic technologies to treat depression and PTSD. NRx Pharmaceuticals is also progressing with filing for Accelerated Approval for NRX-101 and has submitted applications for NRX-100 and ketamine.

Cybin Inc. has obtained approval to launch the EMBRACE Phase 3 study in Ireland, Poland, and Greece as part of their PARADIGM program. The study will evaluate the efficacy of CYB003, a proprietary deuterated psilocin analog, in treating Major Depressive Disorder by enrolling 330 participants across various international sites. Visit www.cybin.com for more information on Cybin and its innovative mental healthcare research pipeline.

Cybin Inc., a neuropsychiatry company, will have CEO Doug Drysdale participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Cybin is dedicated to developing new treatment options for mental health conditions, with ongoing studies on major depressive disorder and generalized anxiety disorder. A live webcast of the event will be available, showcasing Cybin's commitment to transforming mental healthcare.

NRx Pharmaceuticals CEO Prof. Jonathan Javitt will discuss the use of ketamine and other drugs for treating CNS disorders like depression, suicidality, and PTSD at the upcoming BTIG Virtual Biotechnology Conference. The company is focused on developing therapeutics for conditions such as bipolar depression and PTSD, with plans to file for Accelerated Approval for NRX-101 and NRX-100.

Cybin Inc. has obtained approval to commence the second Phase 3 trial for CYB003 in Depression, aiming to enroll 330 patients globally. With a focus on psychedelic-based treatments, the company seeks to address the growing demand for innovative mental health therapies, following the success of esketamine in the sector.